RBC Capital Sticks to Its Buy Rating for Humana (HUM)

RBC Capital analyst Ben Hendrix maintained a Buy rating on Humana (HUM – Research Report) yesterday and set a price target of $353.00. The company’s shares closed yesterday at $315.98.

Hendrix covers the Healthcare sector, focusing on stocks such as Cigna, Brookdale Senior Living, and Humana. According to TipRanks, Hendrix has an average return of 2.8% and a 52.55% success rate on recommended stocks.

Currently, the analyst consensus on Humana is a Moderate Buy with an average price target of $360.79, representing a 14.18% upside. In a report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $350.00 price target.

HUM market cap is currently $39.54B and has a P/E ratio of 16.40.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Humana (HUM) Company Description:

Humana Inc. is a leading health insurance service provider in the United States. The company, through its Retail division, provides medicare benefits and state-based medicaid contracts, which are marketed on a retail basis to individuals. The Group and Specialty business offers employer group commercial fully-insured medical products and specialty health insurance benefits. Humana offers pharmacy solutions, provider services, home-based services, and clinical programs to the company’s health plan members as well as to third parties through the Healthcare Services segment.